epinephrine inhaler (Asthmanefrin, Primatene Mist)
Jump to navigation
Jump to search
Introduction
Asthmanefrin is racemic epinephrine
Indications
Dosage
- 0.5 mL vial contains 11.25 mg racepinephrine (1% epinephrine)
- for use with a battery-operated atomizer that creates a mist that is inhaled into the lungs via a mouthpiece or mask[3]
Notes
- Primatene mist removed from market in 2011 due to use of chlorofluorocarbon (CFC) propellants.
- new version* of over-the-counter Primatene Mist FDA-approved Nov 2018[4]
* metered-dose inhaler works in a different way than its 2011 predecessor[4]
More general terms
Component of
References
- ↑ Prescriber's Letter 13(3): 2006 Status of OTC Epinephrine Inhalers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220311&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Physician's First Watch, Aug 27 2012 Massachusetts Medical Society http://www.jwatch.org
NEPHRON ANNOUNCES ASTHMANEFRINTM, AN ALTERNATIVE TO PRIMATENE <TM> MIST http://www.nephronpharm.com/images/upload_images/file/FL%20Final%20Press%20Release%208-20.pdf - ↑ 3.0 3.1 Prescriber's Letter 19(10): 2012 Asthmanefrin Inhalation Solution Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=281009&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 4.0 4.1 4.2 FDA Statement. Nv 8, 2018 Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm625338.htm